KSIH yields 20000.00% · ABBV yields 3.06%● Live data
📍 KSIH pulled ahead of the other in Year 1
Combined, KSIH + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KSIH + ABBV for your $10,000?
KS International Holdings Corporation focuses on providing solutions and services to individuals seeking to become Internet-based retailers. It operates a Web site, kachingkaching.com, which provides individual Web Store owners with the ability to create, manage, and earn money from product sales generated from their individual online Web stores. The company provides Web Store owners with solutions and resources necessary to create, design, and maintain a Web Store; access to a range of retail goods at competitive prices; and order fulfillment, customer service, and other back-office functions, which assist Web Store Owners with tracking and managing orders and sales from their Web Stores. Its store products include books, DVDs, computers, software, kitchen products, home and garden products, pet supplies, cosmetics and fragrance products, health and wellness products, consumer electronics, cameras, and office supplies. The company was formerly known as KaChing KaChing, Inc. and changed its name to KS International Holdings Corporation in December 2013. KS International Holdings Corporation was founded in 2009 and is headquartered in Taipei City, Taiwan.
Full KSIH Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.